A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
Clinical trial NCT04429087 · RECRUITING
Trial details
- NCT number
- NCT04429087
- Sponsor
- Boehringer Ingelheim
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-29
- Primary completion
- 2026-08-24
- Enrollment
- 300
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.